NewAmsterdam Pharma (NAMS) Competitors

$37.75 -1.14 (-2.93%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$38.01 +0.26 (+0.69%)

As of 07:37 AM Eastern

NAMS vs. SMMT, RGC, BBIO, AXSM, and ELAN

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include Summit Therapeutics (SMMT), Regencell Bioscience (RGC), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market.

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	192.89	-$203.82M	-$1.79	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 21 mentions for NewAmsterdam Pharma and 14 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.17 beat NewAmsterdam Pharma's score of 0.58 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Summit Therapeutics	N/A	-291.24%	-243.07%

NewAmsterdam Pharma presently has a consensus price target of $48.00, indicating a potential upside of 27.15%. Summit Therapeutics has a consensus price target of $27.58, indicating a potential upside of 46.80%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Regencell Bioscience?

NewAmsterdam Pharma (NASDAQ:NAMS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than NewAmsterdam Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	192.89	-$203.82M	-$1.79	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Regencell Bioscience had 7 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 28 mentions for Regencell Bioscience and 21 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.58 beat Regencell Bioscience's score of 0.02 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	21 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Regencell Bioscience has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. Regencell Bioscience's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Regencell Bioscience	N/A	N/A	N/A

NewAmsterdam Pharma presently has a consensus price target of $48.00, indicating a potential upside of 27.15%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

NewAmsterdam Pharma has higher earnings, but lower revenue than BridgeBio Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	192.89	-$203.82M	-$1.79	N/A
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 22 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 43 mentions for BridgeBio Pharma and 21 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.58 beat BridgeBio Pharma's score of 0.54 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BridgeBio Pharma	11 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a net margin of -124.42% compared to NewAmsterdam Pharma's net margin of -943.23%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
BridgeBio Pharma	-124.42%	N/A	-65.81%

NewAmsterdam Pharma presently has a consensus price target of $48.00, indicating a potential upside of 27.15%. BridgeBio Pharma has a consensus price target of $88.19, indicating a potential upside of 28.54%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats NewAmsterdam Pharma on 11 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $251.26, indicating a potential upside of 6.78%. NewAmsterdam Pharma has a consensus price target of $48.00, indicating a potential upside of 27.15%. Given NewAmsterdam Pharma's higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.97	-$183.17M	-$3.73	N/A
NewAmsterdam Pharma	$22.50M	192.89	-$203.82M	-$1.79	N/A

In the previous week, NewAmsterdam Pharma had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for NewAmsterdam Pharma and 8 mentions for Axsome Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.58 beat Axsome Therapeutics' score of -0.03 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Axsome Therapeutics has a net margin of -26.59% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

NewAmsterdam Pharma beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $28.20, indicating a potential upside of 29.14%. NewAmsterdam Pharma has a consensus price target of $48.00, indicating a potential upside of 27.15%. Given Elanco Animal Health's higher possible upside, research analysts clearly believe Elanco Animal Health is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NewAmsterdam Pharma has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.31	-$232M	-$0.50	N/A
NewAmsterdam Pharma	$22.50M	192.89	-$203.82M	-$1.79	N/A

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 21 mentions for NewAmsterdam Pharma and 14 mentions for Elanco Animal Health. NewAmsterdam Pharma's average media sentiment score of 0.58 beat Elanco Animal Health's score of 0.41 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Elanco Animal Health has a net margin of -4.95% compared to NewAmsterdam Pharma's net margin of -943.23%. Elanco Animal Health's return on equity of 7.42% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

Elanco Animal Health beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.47B	$3.04B	$6.30B	$12.28B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-21.09	18.86	21.03	25.58
Price / Sales	192.89	295.51	554.66	78.88
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	6.52	4.35	9.78	6.66
Net Income	-$203.82M	$72.19M	$3.55B	$333.63M
7 Day Performance	8.32%	-1.05%	-0.52%	-0.12%
1 Month Performance	9.61%	-0.02%	1.21%	3.93%
1 Year Performance	101.33%	46.31%	41.26%	36.07%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	3.4127 of 5 stars	$37.75 -2.9%	$48.00 +27.2%	+101.3%	$4.47B	$22.50M	N/A	4	Earnings Report Analyst Revision
SMMT Summit Therapeutics	3.2728 of 5 stars	$17.54 +3.3%	$27.58 +57.3%	-23.6%	$13.61B	N/A	N/A	110	Positive News
RGC Regencell Bioscience	0.3661 of 5 stars	$27.27 -0.3%	N/A	N/A	$13.48B	N/A	N/A	10	Trending News Earnings Report
BBIO BridgeBio Pharma	3.4462 of 5 stars	$68.78 -0.3%	$87.71 +27.5%	+106.3%	$13.47B	$502.08M	N/A	400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
AXSM Axsome Therapeutics	2.228 of 5 stars	$223.06 -0.3%	$251.89 +12.9%	+122.7%	$11.47B	$638.50M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. SMMT, RGC, BBIO, AXSM, and ELAN

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Regencell Bioscience?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. SMMT, RGC, BBIO, AXSM, and ELAN

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Which has more risk and volatility, NAMS or SMMT?

Which has stronger earnings & valuation, NAMS or SMMT?

Does the media favor NAMS or SMMT?

Is NAMS or SMMT more profitable?

Do analysts recommend NAMS or SMMT?

Do insiders and institutionals believe in NAMS or SMMT?

Summary

How does NewAmsterdam Pharma compare to Regencell Bioscience?

Which has more volatility and risk, NAMS or RGC?

Which has preferable earnings & valuation, NAMS or RGC?

Does the media refer more to NAMS or RGC?

Is NAMS or RGC more profitable?

Do analysts prefer NAMS or RGC?

Do institutionals and insiders believe in NAMS or RGC?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Which has more volatility and risk, NAMS or BBIO?

Which has preferable earnings & valuation, NAMS or BBIO?

Does the media refer more to NAMS or BBIO?

Is NAMS or BBIO more profitable?

Do analysts prefer NAMS or BBIO?

Do institutionals and insiders believe in NAMS or BBIO?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or NAMS?

Do analysts rate AXSM or NAMS?

Do insiders & institutionals believe in AXSM or NAMS?

Which has better valuation and earnings, AXSM or NAMS?

Does the media prefer AXSM or NAMS?

Is AXSM or NAMS more profitable?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Which has more risk and volatility, ELAN or NAMS?

Do analysts rate ELAN or NAMS?

Do insiders & institutionals believe in ELAN or NAMS?

Which has better valuation and earnings, ELAN or NAMS?

Does the media prefer ELAN or NAMS?

Is ELAN or NAMS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools